Overview

A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Patients With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib

Status:
Completed

Trial end date:
2010-06-01

Target enrollment:

Participant gender:

Summary

Preclinical studies have shown that SNDX-275 is able to reactivate the expression of EGFR, E-cadherin and ErbB3 expression. The combination of SNDX-275 with erlotinib (an EGFRi) in patients who are progressing on erlotinib will show measurable activity as evidenced by the disease control rate and with an acceptable safety profile.

Phase:

Phase 2

Details

Lead Sponsor:

Syndax Pharmaceuticals

Treatments:

Entinostat
Erlotinib Hydrochloride